Erlotinib is a specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, which is given for locally advanced or metastatic non-small cell lung cancer treatment [10–12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.